Diclofenac inhibits esophageal squamous cell carcinoma through suppression of metabolic pathways and activation of p53 signaling
To investigate the molecular mechanisms of Diclofenac in ESCC cell line TE11 Overall design: We have treated ESCC cell line TE11 with 200 µM of Diclofenac for 48 hours. Then we performed RNA sequencing and Ingenuity Pathway Analysis.